Pitchford is managing director of healthcare investments at Imperial Innovations Group, a UK-listed venture capital firm that primarily supports spin-outs from British universities after its own spin out from Imperial College London.
UK-based biotech company PolyTherics has appointed experienced venture investors Anker Lundemose and Nigel Pitchford to its board.
Pitchford is managing director of healthcare investments at Imperial Innovations Group, a UK-listed venture capital firm that primarily supports spin-outs from British universities after its own spin out from Imperial College London.
Lundemose is co-founder of several companies including Symphogen, Santaris and Prosidion, a UK subsidiary of OSI Pharmaceuticals where he had been a managing director of OSI’s corporate venturing unit.
PolyTherics…
